University of Ljubljana, Faculty of Pharmacy, Slovenia.
Acta Pharm. 2012 Mar;62(1):1-14. doi: 10.2478/v10007-012-0010-5.
Spherical crystallization of drugs is the process of obtaining larger particles by agglomeration during crystallization. The most common techniques used to obtain such particles are spherical agglomeration and quasi-emulsion solvent diffusion. Ammonia diffusion systems and crystallo-co-agglomeration are extensions of these techniques. By controlling process parameters during crystallization, such as temperature, stirring rate, type and amount of solvents, or excipient selection, it is possible to control the formation of agglomerates and obtain spherical particles of the desired size, porosity, or hardness. Researchers have reported that the particles produced have improved micromeritic, physical, and mechanical properties, which make them suitable for direct compression. In some cases, when additional excipients are incorporated during spherical crystallization, biopharmaceutical parameters including the bioavailability of drugs can also be tailored.
药物的球形结晶是在结晶过程中通过团聚获得更大颗粒的过程。获得此类颗粒最常用的技术是球形团聚和准乳液溶剂扩散。氨扩散系统和结晶共团聚是这些技术的延伸。通过在结晶过程中控制工艺参数，例如温度、搅拌速度、溶剂的类型和数量或赋形剂的选择，可以控制团聚体的形成并获得所需尺寸、孔隙率或硬度的球形颗粒。研究人员报告称，所生产的颗粒具有改善的微粉学、物理和机械性能，这使得它们适合直接压缩。在某些情况下，当在球形结晶过程中加入额外的赋形剂时，包括药物生物利用度在内的生物制药参数也可以进行定制。
